Factors  ||| S:0 E:8 ||| NNS
associated  ||| S:8 E:19 ||| VBN
to  ||| S:19 E:22 ||| TO
the  ||| S:22 E:26 ||| DT
use  ||| S:26 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
psychotropic  ||| S:33 E:46 ||| JJ
drugs  ||| S:46 E:52 ||| NNS
by  ||| S:52 E:55 ||| IN
community-dwelling  ||| S:55 E:74 ||| JJ
elderly  ||| S:74 E:82 ||| JJ
in  ||| S:82 E:85 ||| IN
São  ||| S:85 E:89 ||| NNP
Paulo  ||| S:89 E:95 ||| NNP
city  ||| S:95 E:100 ||| NN
The  ||| S:100 E:104 ||| DT
objectives  ||| S:104 E:115 ||| NNS
of  ||| S:115 E:118 ||| IN
study  ||| S:118 E:124 ||| NN
were  ||| S:124 E:129 ||| VBD
to  ||| S:129 E:132 ||| TO
identify  ||| S:132 E:141 ||| VB
the  ||| S:141 E:145 ||| DT
prevalence  ||| S:145 E:156 ||| NN
and  ||| S:156 E:160 ||| CC
factors  ||| S:160 E:168 ||| NNS
associated  ||| S:168 E:179 ||| VBN
to  ||| S:179 E:182 ||| TO
the  ||| S:182 E:186 ||| DT
use  ||| S:186 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
psychotropic  ||| S:193 E:206 ||| JJ
drugs  ||| S:206 E:212 ||| NNS
among  ||| S:212 E:218 ||| IN
elderly  ||| S:218 E:226 ||| JJ
people  ||| S:226 E:233 ||| NNS
in  ||| S:233 E:236 ||| IN
São  ||| S:236 E:240 ||| NNP
Paulo  ||| S:240 E:246 ||| NNP
city ||| S:246 E:250 ||| NN
.  ||| S:250 E:252 ||| .
It  ||| S:252 E:255 ||| PRP
is  ||| S:255 E:258 ||| VBZ
a  ||| S:258 E:260 ||| DT
cross-sectional  ||| S:260 E:276 ||| JJ
study ||| S:276 E:281 ||| NN
.  ||| S:281 E:283 ||| .
Data  ||| S:283 E:288 ||| NNP
were  ||| S:288 E:293 ||| VBD
used  ||| S:293 E:298 ||| VBN
from  ||| S:298 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
SABE  ||| S:307 E:312 ||| NNP
survey  ||| S:312 E:319 ||| NN
( ||| S:319 E:320 ||| -LRB-
for  ||| S:320 E:324 ||| IN
Health ||| S:324 E:330 ||| NNP
,  ||| S:330 E:332 ||| ,
Well-being  ||| S:332 E:343 ||| JJ
and  ||| S:343 E:347 ||| CC
Ageing ||| S:347 E:353 ||| NNP
) ||| S:353 E:354 ||| -RRB-
.  ||| S:354 E:356 ||| .
The  ||| S:356 E:360 ||| DT
sample  ||| S:360 E:367 ||| NN
was  ||| S:367 E:371 ||| VBD
constituted  ||| S:371 E:383 ||| VBN
of  ||| S:383 E:386 ||| IN
1.115  ||| S:386 E:392 ||| CD
elderly  ||| S:392 E:400 ||| JJ
people ||| S:400 E:406 ||| NNS
,  ||| S:406 E:408 ||| ,
aging  ||| S:408 E:414 ||| VBG
65  ||| S:414 E:417 ||| CD
and  ||| S:417 E:421 ||| CC
over ||| S:421 E:425 ||| RB
,  ||| S:425 E:427 ||| ,
which  ||| S:427 E:433 ||| WDT
were  ||| S:433 E:438 ||| VBD
interviewed  ||| S:438 E:450 ||| VBN
by  ||| S:450 E:453 ||| IN
standard  ||| S:453 E:462 ||| JJ
method ||| S:462 E:468 ||| NN
.  ||| S:468 E:470 ||| .
In  ||| S:470 E:473 ||| IN
the  ||| S:473 E:477 ||| DT
data  ||| S:477 E:482 ||| NN
analysis ||| S:482 E:490 ||| NN
,  ||| S:490 E:492 ||| ,
it  ||| S:492 E:495 ||| PRP
was  ||| S:495 E:499 ||| VBD
used  ||| S:499 E:504 ||| VBN
univariate  ||| S:504 E:515 ||| NNS
and  ||| S:515 E:519 ||| CC
multiple  ||| S:519 E:528 ||| JJ
logistic  ||| S:528 E:537 ||| JJ
regression ||| S:537 E:547 ||| NN
,  ||| S:547 E:549 ||| ,
stepwise  ||| S:549 E:558 ||| VBG
forward  ||| S:558 E:566 ||| RP
and  ||| S:566 E:570 ||| CC
level  ||| S:570 E:576 ||| NN
of  ||| S:576 E:579 ||| IN
significance  ||| S:579 E:592 ||| NN
of  ||| S:592 E:595 ||| IN
5 ||| S:595 E:596 ||| CD
% ||| S:596 E:597 ||| NN
.  ||| S:597 E:599 ||| .
The  ||| S:599 E:603 ||| DT
prevalence  ||| S:603 E:614 ||| NN
of  ||| S:614 E:617 ||| IN
the  ||| S:617 E:621 ||| DT
use  ||| S:621 E:625 ||| NN
of  ||| S:625 E:628 ||| IN
psychotropic  ||| S:628 E:641 ||| JJ
drugs  ||| S:641 E:647 ||| NNS
of  ||| S:647 E:650 ||| IN
12,2 ||| S:650 E:654 ||| CD
%  ||| S:654 E:656 ||| NN
and  ||| S:656 E:660 ||| CC
the  ||| S:660 E:664 ||| DT
factors  ||| S:664 E:672 ||| NNS
associated  ||| S:672 E:683 ||| VBN
were  ||| S:683 E:688 ||| VBD
female  ||| S:688 E:695 ||| JJ
gender  ||| S:695 E:702 ||| NN
( ||| S:702 E:703 ||| -LRB-
OR=3,04  ||| S:703 E:711 ||| CD
IC95 ||| S:711 E:715 ||| CD
% ||| S:715 E:716 ||| NN
=  ||| S:716 E:718 ||| SYM
1,76-5,23 ||| S:718 E:727 ||| CD
)  ||| S:727 E:729 ||| -RRB-
and  ||| S:729 E:733 ||| CC
polypharmacy  ||| S:733 E:746 ||| NNS
( ||| S:746 E:747 ||| -LRB-
OR=4,91  ||| S:747 E:755 ||| CD
IC95 ||| S:755 E:759 ||| CD
% ||| S:759 E:760 ||| NN
=2,74-8,79 ||| S:760 E:770 ||| CD
) ||| S:770 E:771 ||| -RRB-
.  ||| S:771 E:773 ||| .
The  ||| S:773 E:777 ||| DT
use  ||| S:777 E:781 ||| NN
of  ||| S:781 E:784 ||| IN
psychotropics  ||| S:784 E:798 ||| JJ
drugs  ||| S:798 E:804 ||| NNS
by  ||| S:804 E:807 ||| IN
the  ||| S:807 E:811 ||| DT
elderly  ||| S:811 E:819 ||| NN
must  ||| S:819 E:824 ||| MD
have  ||| S:824 E:829 ||| VB
their  ||| S:829 E:835 ||| PRP$
benefits  ||| S:835 E:844 ||| NNS
and  ||| S:844 E:848 ||| CC
risks  ||| S:848 E:854 ||| NNS
very  ||| S:854 E:859 ||| RB
well  ||| S:859 E:864 ||| RB
established ||| S:864 E:875 ||| VBN
.  ||| S:875 E:877 ||| .
Elder  ||| S:877 E:883 ||| JJ
women ||| S:883 E:888 ||| NNS
,  ||| S:888 E:890 ||| ,
especially  ||| S:890 E:901 ||| RB
those  ||| S:901 E:907 ||| DT
who  ||| S:907 E:911 ||| WP
were  ||| S:911 E:916 ||| VBD
submitted  ||| S:916 E:926 ||| VBN
to  ||| S:926 E:929 ||| TO
a  ||| S:929 E:931 ||| DT
polipharmacy ||| S:931 E:943 ||| NN
,  ||| S:943 E:945 ||| ,
deserve  ||| S:945 E:953 ||| VBP
special  ||| S:953 E:961 ||| JJ
attention  ||| S:961 E:971 ||| NN
to  ||| S:971 E:974 ||| TO
adjust  ||| S:974 E:981 ||| VB
dosage  ||| S:981 E:988 ||| NNS
and  ||| S:988 E:992 ||| CC
duration  ||| S:992 E:1001 ||| NN
of  ||| S:1001 E:1004 ||| IN
the  ||| S:1004 E:1008 ||| DT
treatment ||| S:1008 E:1017 ||| NN
,  ||| S:1017 E:1019 ||| ,
with  ||| S:1019 E:1024 ||| IN
the  ||| S:1024 E:1028 ||| DT
purpose  ||| S:1028 E:1036 ||| NN
of  ||| S:1036 E:1039 ||| IN
minimizing  ||| S:1039 E:1050 ||| VBG
the  ||| S:1050 E:1054 ||| DT
adverse  ||| S:1054 E:1062 ||| JJ
outcomes ||| S:1062 E:1070 ||| NNS
.  ||| S:1070 E:1072 ||| .
